Artios Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Artios Pharma sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Artios Pharma: 5 sponsored US clinical trials, 1 recruiting.
Artios Pharma sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acinar Cell Carcinoma, with 1 trials.
Upper-quartile sponsor footprint
Artios Pharma sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
NCT05898399
Study of ART0380 in Patients With Biologically Selected Solid Tumors
NCT05798611
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04991480
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
NCT04976803
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
What is open in the Artios Pharma pipeline
1 recruiting of 5 indexed (20% open); 2 completed (40%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Acinar Cell Carcinoma (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Artios Pharma: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Artios Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this Artios Pharma page
5 registered trials is a research-attention snapshot, not an endorsement of Artios Pharma or any single study.
- 1 of Artios Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acinar Cell Carcinoma is the condition Artios Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acinar Cell Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Artios Pharma pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.